Vedolizumab and the gut–CNS axis in multiple sclerosis: considering T cell licensing pathways
Therapeutic Advances in Neurological Disorders
Published online on February 19, 2026
Abstract
Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
Background:The role of gut-mediated T cell licensing in multiple sclerosis (MS) remains incompletely understood.Objective:We hypothesized that T cell licensing in the gut contributes to MS pathogenesis and evaluated whether vedolizumab—an anti-α4β7 ...
Background:The role of gut-mediated T cell licensing in multiple sclerosis (MS) remains incompletely understood.Objective:We hypothesized that T cell licensing in the gut contributes to MS pathogenesis and evaluated whether vedolizumab—an anti-α4β7 ...